The inhibitory effects of sweroside on the NLRP3 inflammasome in macrophages and liver tissues are linked to its preventive effects on the pathological symptoms of NASH, such as hepatic inflammation, triglyceride accumulation, and fibrosis. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.